Trial Profile
A mono-institutional, prospective study to evaluate the metabolic response to enzalutamide assessed by choline positron emission tomography in patients with castration resistant prostate cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Sep 2015
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 02 Sep 2015 New trial record